Drug of Abuse Testing Market (By Drug Type: Alcohol, Cocaine, Marijuana/Cannabis, LSD, Opioids, and Others; By Sample Type: Urine, Saliva, Blood, and others; By End User: Workplaces, Criminal Justice Systems, Hospitals, and Research Labs) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 - 2032
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Drug of Abuse Testing Market, By Drug
7.1. Drug of Abuse Testing Market, by Drug Type, 2021-2030
7.1.1. Alcohol
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Cocaine
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Marijuana/Cannabis
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. LSD
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Opioids
7.1.5.1. Market Revenue and Forecast (2019-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Drug of Abuse Testing Market, By End User
8.1. Drug of Abuse Testing Market, by End User, 2021-2030
8.1.1. Workplaces
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Criminal Justice Systems
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hospitals
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Research Labs
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug of Abuse Testing Market, By Sample
9.1. Drug of Abuse Testing Market, by Sample, 2021-2030
9.1.1. Urine
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Saliva
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Blood
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug of Abuse Testing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.3. Market Revenue and Forecast, by Sample (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.7.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.7.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.7.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Sample (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Sample (2019-2030)
Chapter 11. Company Profiles
11.1. Danaher Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. LabCorp
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Quest Diagnostics, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Cordant Health Solutions
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. DrugScan
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Legacy Medical Services
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Mayo Clinic Laboratories
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. LGC Group
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Precision Diagnostics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample